RVP

Drug Catalog - Product Detail

OSELTAMIVIR CAPS 75MG 1 X 10 UNIT DOSES

NDC Mfr Size Str Form
64380-0799-01 STRIDES PHARMA 10 75MG NA
Product Image

PACKAGE FILES

Package Image
Package Image
Generic Name
Substance Name
Product Type
Route
Application Number
Description
11 DESCRIPTION Oseltamivir phosphate, an influenza neuraminidase inhibitor (NAI) is available as capsules containing 30 mg, 45 mg, or 75 mg oseltamivir for oral use, in the form of oseltamivir phosphate USP. In addition to the active ingredient, each capsule contains pregelatinized starch, talc, povidone, croscarmellose sodium, isopropyl alcohol and sodium stearyl fumarate.The 30 mg capsule shell contains gelatin, titanium dioxide, water and iron oxide yellow. The 45 mg capsule shell contains gelatin, titanium dioxide, water and iron oxide black. The 75 mg capsule shell contains gelatin, titanium dioxide, water, Iron oxide yellow, Iron oxide red and Sodium lauryl sulfate. Imprinting ink contains shellac, black iron oxide, potassium hydroxide. Oseltamivir phosphate is a White to off-white powder with the chemical name (3R, 4R, 5S) -4-acetylamino-5amino-3(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid, ethyl ester, phosphate (1:1). The chemical formula is C 16 H 28 N 2 O 4 (free base). The molecular weight is 312.4 for oseltamivir free base and 410.4 for oseltamivir phosphate salt. The structural formula is as follows: Chemical Structure
How Supplied
16 HOW SUPPLIED/STORAGE AND HANDLING Oseltamivir phosphate capsules USP 30-mg capsules (30 mg free base equivalent of the phosphate salt): White to off white powder filled in size "4" hard gelatin capsule with light yellow opaque cap/body printed 30 on cap and OP on body in black. Available in blister packages of 10 (NDC 64380-797-01). 45-mg capsules (45 mg free base equivalent of the phosphate salt): White to off white powder filled in size "3" hard gelatin capsule with grey opaque cap/body printed 45 on cap and OP on body in black. Available in blister packages of 10 (NDC 64380-798-01). 75-mg capsules (75 mg free base equivalent of the phosphate salt): White to off white powder filled in size "2" hard gelatin capsule with cream cap and brown body printed OP on cap and 75 on body in black. Available in blister packages of 10 (NDC 64380-799-01). Storage Store at 20° to 25°C (68° to 77°F); Excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].
Indications & Usage
1 INDICATIONS AND USAGE Oseltamivir Phosphate capsule USP is an influenza neuraminidase inhibitor (NAI) indicated for: Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. ( 1.1 ) Prophylaxis of influenza A and B in patients 1 year and older. ( 1.2 ) Limitations of Use : Not a substitute for annual influenza vaccination. ( 1.3 ) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. ( 1.3 ) Not recommended for patients with end-stage renal disease not undergoing dialysis. ( 1.3 ) 1.1 Treatment of Influenza Oseltamivir Phosphate capsule USP is indicated for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. 1.2 Prophylaxis of Influenza Oseltamivir Phosphate capsule USP is indicated for the prophylaxis of influenza A and B in patients 1 year and older. 1.3 Limitations of Use Oseltamivir Phosphate capsule USP is not a substitute for early influenza vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. Influenza viruses change over time. Emergence of resistance substitutions could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use Oseltamivir Phosphate Capsule USP [see Microbiology ( 12.4 )]. Oseltamivir Phosphate capsule USP is not recommended for patients with end-stage renal disease not undergoing dialysis [see Dosage and Administration ( 2.4 ) and Use in Specific Populations ( 8.6 )].
Dosage and Administration
2 DOSAGE AND ADMINISTRATION Treatment of influenza Adults and adolescents (13 years and older): 75 mg twice daily for 5 days (2.2) Paediatric patients 1 to 12 years of age: Based on weight twice daily for 5 days (2.2) Paediatric patients 2 weeks to less than 1 year of age: 3mg/kg twice daily for 5 days (2.2) Renally impaired adult patients (creatinine clearance >30-60 mL/min): Reduce to 30 mg twice daily for 5 days ( 2.4 ) Renally impaired adult patients (creatinine clearance >10-30 mL/min): Reduce to 30 mg once daily for 5 days ( 2.4 ) ESRD patients on hemodialysis: Reduce to 30 mg immediately and then 30 mg after every hemodialysis cycle. Treatment duration not to exceed 5 days ( 2.4 ) ESRD patients on CAPD: Reduce to a single 30 mg dose immediately ( 2.4 ) Prophylaxis of influenza Adults and adolescents (13 years and older): 75 mg once daily for at least 10 days (2.3) Community outbreak: 75 mg once daily for up to 6 weeks (2.3) Pediatric patients 1 to 12 years of age: Based on weight once daily for 10 days (2.3) Community outbreak: Based on weight once daily for up to 6 weeks (2.3) Renally impaired adult patients (creatinine clearance >30-60 mL/min): Reduce to 30 mg once daily ( 2.4 ) Renally impaired adult patients (creatinine clearance >10-30 mL/min): Reduce to 30 mg once every other day ( 2.4 ) ESRD patients on hemodialysis: Reduce to 30 mg immediately and then 30 mg after alternate hemodialysis cycles for the recommended duration of prophylaxis ( 2.4 ) ESRD patients on CAPD: Reduce to 30 mg immediately and then 30 mg once weekly for the recommended duration of prophylaxis ( 2.4 ) 2.1 Dosage and Administration Overview Administer Oseltamivir Phosphate capsule for the treatment of influenza in patients 2 weeks of age or older [see Dosage and Administration ( 2.2 )] or for prophylaxis of influenza in patients 1 year and older [see Dosage and Administration ( 2.3 )] using: Oseltamivir Phosphate capsule The capsules may be taken with or without food; however, tolerability may be enhanced if Oseltamivir Phosphate capsule USP is taken with food. Adjust the Oseltamivir Phosphate capsule dosage in patients with moderate or severe renal impairment [see Dosage and Administration (2.4)] For patients who cannot swallow capsules, Oseltamivir Phosphate for oral suspension is the preferred formulation. When oseltamivir phosphate for oral suspension is not available from wholesaler or the manufacturer, Oseltamivir Phosphate capsules may be opened and mixed with sweetened liquids such as regular or sugar-free chocolate syrup, corn syrup, caramel topping, or light brown sugar (dissolved in water). During emergency situation and when neither the oral suspension or the age-appropriate strengths of Oseltamivir Phosphate capsules to mix with sweetened liquids are available, then a pharmacist may prepare an emergency supply of oral suspension from Oseltamivir Phosphate 75 mg capsules [see Dosage and Administration (2.6)] . 2.2 Recommended Dosage for Treatment of Influenza Initiate treatment with Oseltamivir phosphate capsule within 48 hours of influenza symptom onset. Adults and Adolescents (13 years of age and older) The recommended oral dosage of Oseltamivir phosphate capsule for treatment of influenza in adults and adolescents 13 years and older is 75 mg twice daily (one 75mg capsule twice daily) for 5 days. Pediatric Patients (2 weeks of age through 12 years of age) Table 1 displays the recommended oral dose of Oseltamivir phosphate capsule for treatment of influenza in pediatric patients 2 weeks of age through 12 years of age and provides information about prescribing the capsule. 2.3 Recommended Dosage for Prophylaxis of Influenza Initiate post-exposure prophylaxis with Oseltamivir phosphate capsule within 48 hours following close contact with an infected individual. Initiate seasonal prophylaxis with Oseltamivir phosphate capsule during a community outbreak. Adults and Adolescents (13 years of age and older) The recommended dosage of oseltamivir phosphate capsule USP for prophylaxis of influenza in adults and adolescents 13 years and older is 75 mg orally once daily (one 75 mg capsule once daily) for at least 10 days following close contact with an infected individual and up to 6 weeks during a community outbreak. In immunocompromised patients, Oseltamivir phosphate capsule may be continued for up to 12 weeks [see Use in Specific Populations ( 8.9 )]. The duration of protection lasts for as long as Oseltamivir phosphate capsule dosing is continued. Pediatric Patients (1 to 12 years of age) Table 1 displays the recommended oral dose of Oseltamivir phosphate capsule for prophylaxis of influenza in pediatric patients 1 to 12 years of age based on body weight and provides information about prescribing the capsule. Prophylaxis in pediatric patients is recommended for 10 days following close contact with an infected individual and up to 6 weeks during a community outbreak [see Use in Specific Populations ( 8.4 ) and Clinical Studies ( 14.2 )]. Table 1 Oseltamivir phosphate capsules Dosage Recommendations in Pediatric Patients for Treatment and Prophylaxis of Influenza Weight Treatment Dosage for 5 days Prophylaxis Dosage for 10 days The recommended duration for post-exposure prophylaxis is 10 days and the recommended duration for community outbreak (seasonal/pre-exposure) prophylaxis is up to 6 weeks (or up to 12 weeks in immunocompromised patients). The amount supplied (e.g., number of bottles or capsules) for seasonal prophylaxis may be greater than for post-exposure prophylaxis. Number of Capsules to Dispense (Strength) Oseltamivir phosphate for oral suspension is the preferred formulation for patients who cannot swallow capsules. Patients from 2 Weeks to less than 1 Year of Age Any weight 3 mg/kg twice daily Not applicable Not applicable Patients 1 to 12 Years of Age Based on Body Weight 15 kg or less 30 mg twice daily 30 mg once daily 10 Capsules (30 mg) 15.1 kg to 23 kg 45 mg twice daily 45 mg once daily 10 Capsules (45 mg) 23.1 kg to 40 kg 60 mg twice daily 60 mg once daily 20 Capsules (30 mg) 40.1 kg or more 75 mg twice daily 75 mg once daily 10 capsules (75 mg) 2.4 Dosage in Patients with Renal Impairment Table 2 displays the dosage recommendations for the treatment and prophylaxis of influenza in adults with various stages of renal impairment (estimated creatinine clearance of less than or equal to 90 mL per minute). Dosage modifications are recommended in adults with estimated creatinine clearance less than or equal to 60 mL per minute [ see Use in specific Population ( 8.6 ) and Clinical Pharmacology ( 12.3 ) ]. Table 2 Recommended Dose Modifications for Treatment and Prophylaxis of Influenza in Adults with Renal Impairment or End Stage Renal Disease (ESRD) on Dialysis * Capsules can be used for 30 mg dosing. † The recommended duration for post-exposure prophylaxis is at least 10 days and the recommended duration for community outbreak (seasonal/pre-exposure) prophylaxis is up to 6 weeks (or up to 12 weeks in immunocompromised patients). $ Data derived from studies in continuous ambulatory peritoneal dialysis (CAPD) patients. Renal Impairment (Creatinine Clearance) Recommended Treatment Regimen * Recommended Prophylaxis Regimen *† Mild (>60-90 mL/minute) 75 mg twice daily for 5 days 75 mg once daily Moderate (>30-60 mL/minute) 30 mg twice daily for 5 days 30 mg once daily Severe (>10-30 mL/ minute) 30 mg once daily for 5 days 30 mg every other day ESRD Patients on Hemodialysis (≤10 mL/ minute) 30 mg immediately and then 30 mg after every hemodialysis cycle. (treatment duration not to exceed 5 days) 30 mg immediately and then 30 mg after alternate hemodialysis cycles. ESRD Patients on Continuous Ambulatory Peritoneal Dialysis $ (≤10 mL/ minute) A single 30 mg dose administered immediately 30 mg immediately and then 30 mg once weekly. ESRD Patients not on Dialysis Oseltamivir Phosphate capsule is not recommended Oseltamivir Phosphate capsule is not recommended 2.6 Emergency Preparation of Oral Suspension from 75 mg Oseltamivir Phospate Capsules The following directions are provided for use only during emergency situations and when FDA-approved, commercially manufactured Oseltamivir Phosphate for oral suspension is not available from wholesalers or the manufacturer. The following emergency preparation instructions will provide one patient with enough Oseltamivir Phosphate for a 5-day course of treatment of influenza or a 10-day course of prophylaxis of influenza: Step #1 : Determine the dosage of Oseltamivir Phosphate capsule USP for the patient [see Dosage and Administration ( 2.2 , 2.3 , and 2.4 )] then determine the total volume of oral suspension needed to be prepared (see Table 3). Table 3 Emergency Preparation: Volume of Prepared Oral Suspension (6 mg per mL) Based upon Oseltamivir Phosphate Dose Oseltamivir Phosphate Dose If the oseltamivir phosphate dose is between the doses listed, use the greater listed dose to determine the total volume of prepared oral suspension. Total Volume to Prepare per Patient 15 mg or less 37.5 mL 30 mg 75 mL 45 mg 100 mL 60 mg 125 mL 75 mg 150 mL Step #2 : Preparation must be performed with only one of the following vehicles (other vehicles have been studied): Cherry Syrup (Humco ® ), Ora-Sweet ® SF (sugar-free) (Paddock Laboratories), or simple syrup. Determine the number of capsules and the amount of water and vehicle needed to prepare the total volume (see Table 3) of prepared oral suspension (6 mg per ml) for a complete treatment or prophylaxis course (See Table 4). Table 4 Emergency Preparation: Number of Oseltamivir Phosphate 75mg Capsules and Amount of Water and Vehicle Needed to prepare the Total Volume of a Prepared Oral Suspension (6 mg per mL) Total Volume of Prepared Oral Suspension 37.5 mL 75 mL 100 mL 125 mL 150 mL Number of Oseltamivir Phosphate 75 mg Capsules (Total Strength) Includes overage to ensure all doses can be delivered 3 (225 mg) 6 (450 mg) 8 (600 mg) 10 (750 mg) 12 (900 mg) Amount of Water 2.5 mL 5 mL 7 mL 8 mL 10 mL Volume of Vehicle Cherry Syrup (Humco ® ) OR Ora-Sweet ® SF (Paddock Laboratories) OR simple syrup 34.5 mL 69 mL 91 mL 115 mL 137 mL Step #3 : Follow the instruction below for preparing the 75mg Oseltamivir Phosphate Capsules to produce oral suspension (6mg/ mL): a) Place the specified amount of water into a polyethyleneterephthalate (PET) or glass bottle (see Table 4). Constitution in other bottle types is not recommended because there is no stability data with other bottle types. b) Carefully separate the capsule body and cap and pour the contents of the required number of Oseltamivir Phosphate 75 mg Capsules into the PET or glass bottle. c) Gently swirl the suspension to ensure adequate wetting of the Oseltamivir phosphate capsules powder for at least 2 minutes. d) Slowly add the specified amount of vehicle to the bottle. e) Close the bottle using a child-resistant cap and shake well for 30 seconds to completely dissolve the active drug and to ensure homogeneous distribution of the dissolved drug in the resulting suspension, The active drug, Oseltamivir Phosphate, readily dissolves in the specified vehicles. The suspension is caused by inert ingredients of Oseltamivir Phosphate Capsules which are insoluble in these vehicles. f) Put an ancillary label on the bottle indicating "Shake Well Before Use." g) Instruct the parent or caregiver that any unused suspension remaining in the bottle following completion of therapy must be discarded by either affixing an ancillary label to the bottle or adding a statement to the pharmacy label instructions. h) Place a pharmacy label on the bottle that include the patient's name, dosing instructions, drug name and any other required information to be in compliance with all State and Federal Pharmacy Regulations. Place an appropriate expiration date on the label according to storage condition below. i) Include the recommended dosage on the pharmacy label as per Tables 1 and 2 [See Dosage and Administration ( 2.2 , 2.3 , and 2.4 )] j) Store the prepared oral suspension in glass or PET bottle either: In a refrigerator: [2° to 8°C (36° to 46°F)]: Stable for 5 weeks when stored in a refrigerator. At room Temperature [25°C (77°F)]: Stable for 5 days when stored at room temperature.